SAN CARLOS, Calif.--Nov 10, 2025--CuraSen Therapeutics, Inc., a biopharmaceutical company developing drug candidates with broad applicability in neurodegenerative and neuropsychiatric diseases, today announced encouraging results from a Phase 1 study...
Pappas Capital Strengthens Team with Appointment of W. Richard Staub as Venture Partner
RESEARCH TRIANGLE PARK, N.C., Dec. 13, 2022 -- Pappas Capital, a global venture capital and commercial development firm, announced today the appointment of Richard Staub as Venture Partner. His appointment will strengthen the Pappas Capital team in support of the firm's continued growth and expansion.
